TRACON Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
TRACON Pharmaceuticals (Nasdaq: TCON) will present a corporate overview at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TRACON Pharmaceuticals (Nasdaq: TCON) will present a corporate overview at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020, at 12:00 pm EDT. The live webcast can be accessed on their website, with a replay available afterward. TRACON focuses on targeted cancer therapeutics, utilizing a CRO-independent development platform. Their pipeline includes Envafolimab for sarcoma, TRC253 for prostate cancer, TRC102 for lung cancer, and TJ004309 for advanced solid tumors. The company seeks partnerships for U.S. regulatory and clinical development.
Details
News Market Reaction – TCON
The recorded move for TCON in the trading session of this news was +18.49%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present a corporate overview at the H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16th, at 12:00 pm EDT.
To access a live webcast of the presentation, please visit the “Events and Presentations” page within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will also be available following the event.
About TRACON
TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a subcutaneous PD-L1 single-domain antibody being developed for the treatment of sarcoma with the goal of initiating a registrational trial in the U.S. in the fourth quarter of 2020; TRC253, a small molecule drug candidate for the treatment of prostate cancer; TRC102, a Phase 2 small molecule drug candidate being developed for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.
| Company Contact: | Investor Contact: |
| Mark Wiggins | Brian Ritchie |
| Chief Business Officer | LifeSci Advisors LLC |
| (858) 251-3492 | 212-915-2578 |
| mwiggins@traconpharma.com | britchie@lifesciadvisors.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.